News

Pittsburgh’s Thar Pharmaceuticals raises $1.2M

Thar Pharmaceuticals Inc. has raised $1.2 million in debt financing to commercialize drugs based on supercritical fluid technologies, according to a regulatory filing.

PITTSBURGH, Pennsylvania — Thar Pharmaceuticals Inc. has raised $1.2 million in debt financing to commercialize drugs based on supercritical fluid technologies, according to a regulatory filing.

Supercritical fluids have no surface tension and are created by combining high temperatures and pressure to bring a substance to its critical point — the point at which the boundary between fluid and gas disappears. Supercritical carbon dioxide can be used as a means of drug delivery.

Thar Pharmaceuticals is a unit of Thar Technologies, which was founded in 1990 by Dr. Lalit Chordia, according to the latter company’s Web site. Thar Pharmaceuticals seeks to develop new forms of existing drugs with improved efficacy, absorption, safety or toxicity.

sponsored content

A Deep-dive Into Specialty Pharma

A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.

The company is looking to raise $1.5 million and has thus far brought in $1.24 million of that amount, according to the filing. Brian Moyer, Thar’s director of corporate development, didn’t immediately return a call.